PURPOSE: To evaluate high-dose-rate (HDR) stereotactic brachytherapy (STBT) for glioblastoma multiforme (GBM). MATERIALS AND METHODS: Between August 1994 and December 1998, 28 patients with newly diagnosed GBM underwent surgery, external-beam radiotherapy (EBRT) and HDR STBT. STBT eligibility criteria included unifocal lesions, residual tumor < or = 6 cm in maximum diameter, supratentorial lesions, tumors not crossing the midline, tumors without subependymal spread and Karnofsky performance status (KPS) > 60. STBT was delivered over five consecutive days with two fractions per day for a total median dose of 30 Gy. Twenty-eight STBT eligible GBM patients treated with surgery and EBRT only over the same period were matched controls. RESULTS: Median survival times for the STBT group and controls were 19.5 versus 12.5 months; one and two year survival rates were 89% versus 42% and 61% versus 28%, respectively (p = 0.12). Using multivariate analysis, age, KPS and HDR STBT were significant factors predicting survival. By RPA class, 2-year survival rates for STBT and controls were: III--78% versus 50%; IV--40% versus 0%; V--21% versus 15%, respectively. Corresponding median survival times in months were: 41.6 versus 21.2 (p = 0.39); 16.7 versus 12.1 (p = 0.36); 18.7 versus 10.6 (p = 0.02). No major complications were found in the STBT arm. CONCLUSIONS: Because of small patient numbers, median survival time increases were only statistically significant in the RPA Class V patients, but a strong survival time trend emerged favoring patients undergoing HDR STBT. Further prospective study is warranted to fully assess the merits of this technique for GBM management.
PURPOSE: To evaluate high-dose-rate (HDR) stereotactic brachytherapy (STBT) for glioblastoma multiforme (GBM). MATERIALS AND METHODS: Between August 1994 and December 1998, 28 patients with newly diagnosed GBM underwent surgery, external-beam radiotherapy (EBRT) and HDR STBT. STBT eligibility criteria included unifocal lesions, residual tumor < or = 6 cm in maximum diameter, supratentorial lesions, tumors not crossing the midline, tumors without subependymal spread and Karnofsky performance status (KPS) > 60. STBT was delivered over five consecutive days with two fractions per day for a total median dose of 30 Gy. Twenty-eight STBT eligible GBM patients treated with surgery and EBRT only over the same period were matched controls. RESULTS: Median survival times for the STBT group and controls were 19.5 versus 12.5 months; one and two year survival rates were 89% versus 42% and 61% versus 28%, respectively (p = 0.12). Using multivariate analysis, age, KPS and HDR STBT were significant factors predicting survival. By RPA class, 2-year survival rates for STBT and controls were: III--78% versus 50%; IV--40% versus 0%; V--21% versus 15%, respectively. Corresponding median survival times in months were: 41.6 versus 21.2 (p = 0.39); 16.7 versus 12.1 (p = 0.36); 18.7 versus 10.6 (p = 0.02). No major complications were found in the STBT arm. CONCLUSIONS: Because of small patient numbers, median survival time increases were only statistically significant in the RPA Class V patients, but a strong survival time trend emerged favoring patients undergoing HDR STBT. Further prospective study is warranted to fully assess the merits of this technique for GBM management.
Authors: P H Gutin; S A Leibel; W M Wara; A Choucair; V A Levin; T L Philips; P Silver; V Da Silva; M S Edwards; R L Davis Journal: J Neurosurg Date: 1987-12 Impact factor: 5.115
Authors: P K Sneed; P R Stauffer; M W McDermott; C J Diederich; K R Lamborn; M D Prados; S Chang; K A Weaver; L Spry; M K Malec; S A Lamb; B Voss; R L Davis; W M Wara; D A Larson; T L Phillips; P H Gutin Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-15 Impact factor: 7.038
Authors: N J Laperriere; P M Leung; S McKenzie; M Milosevic; S Wong; J Glen; M Pintilie; M Bernstein Journal: Int J Radiat Oncol Biol Phys Date: 1998-07-15 Impact factor: 7.038
Authors: J N Sarkaria; D G Petereit; J A Stitt; T Hartman; R Chappell; B R Thomadsen; D A Buchler; J F Fowler; T J Kinsella Journal: Int J Radiat Oncol Biol Phys Date: 1994-08-30 Impact factor: 7.038
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: R C Florell; D R Macdonald; W D Irish; M Bernstein; S A Leibel; P H Gutin; J G Cairncross Journal: J Neurosurg Date: 1992-02 Impact factor: 5.115
Authors: A Martinez; J Gonzalez; J Stromberg; G Edmundson; M Plunkett; G Gustafson; D Brown; D Yan; F Vicini; D Brabbins Journal: Int J Radiat Oncol Biol Phys Date: 1995-12-01 Impact factor: 7.038
Authors: John Buatti; Timothy C Ryken; Mark C Smith; Penny Sneed; John H Suh; Minesh Mehta; Jeffrey J Olson Journal: J Neurooncol Date: 2008-08-20 Impact factor: 4.130
Authors: Alan T Villavicencio; Sigita Burneikiene; Pantaleo Romanelli; Laura Fariselli; Lee McNeely; John D Lipani; Steven D Chang; E Lee Nelson; Melinda McIntyre; Giovanni Broggi; John R Adler Journal: Neurosurg Rev Date: 2009-07-25 Impact factor: 3.042
Authors: Carl J Fisher; Carolyn Niu; Warren Foltz; Yonghong Chen; Elena Sidorova-Darmos; James H Eubanks; Lothar Lilge Journal: PLoS One Date: 2017-07-31 Impact factor: 3.240
Authors: Manjunatha Akathatti Munegowda; Carl Fisher; Daniel Molehuis; Warren Foltz; Mark Roufaiel; Jay Bassan; Mark Nitz; Arkady Mandel; Lothar Lilge Journal: Neurooncol Adv Date: 2019-05-28